P
Patrick Henry Beusker
Researcher at Radboud University Nijmegen
Publications - 35
Citations - 1028
Patrick Henry Beusker is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Semisynthesis & Moiety. The author has an hindex of 9, co-authored 35 publications receiving 931 citations. Previous affiliations of Patrick Henry Beusker include University of Göttingen.
Papers
More filters
Journal ArticleDOI
“Cascade‐Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core
Franciscus M. H. de Groot,Carsten Albrecht,Ralph Koekkoek,Patrick Henry Beusker,Hans W. Scheeren +4 more
TL;DR: Dendrimers that have beenbuilttocompletely and rapidly dissociate intoseparate building blocksupon a single triggeringevent in the dendritic core are reported.
Journal ArticleDOI
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Ronald Christiaan Elgersma,Ruud Coumans,Tijl Huijbregts,Wiro Michaël Petrus Bernardus Menge,John Joosten,Henri Johannes Spijker,Franciscus M. H. de Groot,Miranda M.C. van der Lee,Ruud Ubink,Diels van den Dobbelsteen,David F. Egging,Wim H. A. Dokter,GF Verheijden,Jacques M. Lemmens,C. Marco Timmers,Patrick Henry Beusker +15 more
TL;DR: This work sets out to develop a new class of linker-drugs based on duocarmycins, potent DNA-alkylating agents that are composed of a DNA-alksylating and aDNA-binding moiety and that bind into the minor groove of DNA.
Patent
Prodrugs built as multiple self-elimination-release spacers
TL;DR: In this paper, the authors introduce the concept of multiple release spacers and spacer systems, which can release multiple leaving groups following a single activation of a specifier linked to two or more of the same or different leaving groups.
Journal ArticleDOI
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M.C. van der Lee,Patrick G. Groothuis,Ruud Ubink,Monique van der Vleuten,Tanja van Achterberg,Eline Loosveld,Desiree Damming,Danielle Jacobs,Myrthe Rouwette,David F. Egging,Diels van den Dobbelsteen,Patrick Henry Beusker,Peter Goedings,GF Verheijden,Jacques M. Lemmens,Marco Timmers,Wim H. A. Dokter +16 more
TL;DR: In vivo antitumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models, whereas T-DM1 only showed significant antitumors activity in HER 2 3+ breast cancerPDX models.
Patent
Water-soluble CC-1065 analogs and their conjugates
Patrick Henry Beusker,Groot Franciscus Marinus Hendrikus De,Lutz F. Tietze,Felix Major,Johannes Albertus Frederikus Joosten,Henri Johannes Spijker +5 more
TL;DR: In this paper, the authors proposed a novel analogs of the DNA-binding alkylating agent CC-1065 and their conjugates, which are designed to release their payload after one or more activation steps and/or at a rate and time span controlled by the conjugate.